Also known as: Leqselvi, CTP-543
Oral JAK1/JAK2 inhibitor FDA-approved in 2024 for severe alopecia areata.
Deuruxolitinib is a deuterated form of ruxolitinib that selectively inhibits JAK1 and JAK2. Deuteration improves metabolic stability and pharmacokinetic properties. Like baricitinib, it suppresses the interferon-gamma-driven autoimmune response that destroys the hair follicle immune privilege in alopecia areata.
Unlock Premium Content
Get full access to in-depth analyses, cited studies, premium articles, and AI chat.
$12/mo
View pricing